Autumn Glory Partners’s GSK GSK Stock Holding History

Autumn Glory Partners’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-7,544	Closed	-$268K	–	153
2023 Q1	$268K	Buy	+7,544	New	+$264K	0.23%	101
2022 Q3	–	Sell	-3,772	Closed	-$205K	–	160
2022 Q2	$205K	Sell	3,772 -3,772	-50%	-$208K	0.15%	144
2022 Q1	$410K	Buy	7,544 +3,772	+100%	+$205K	0.24%	110
2021 Q4	$208K	Buy	+3,772	New	+$196K	0.09%	202

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Autumn Glory Partners's GSK Position: Q2 2023 in Review

Autumn Glory Partners sold out of GSK (GSK) in Q2 2023, closing a stake of 7,544 shares — an estimated $268K sold.

Autumn Glory Partners first reported a position in GSK in Q4 2021 and held it in 4 quarters. The position peaked at $410K in Q1 2022. 827 funds tracked by Wall St. Rank hold GSK as of Q2 2023.

Autumn Glory Partners reported no remaining GSK position as of Q2 2023 after selling out during the quarter.
Autumn Glory Partners sold 7,544 GSK shares in Q2 2023, an estimated $268K.
Autumn Glory Partners first reported a position in GSK in Q4 2021 and held it in 4 quarters.
Autumn Glory Partners's GSK position peaked at $410K in Q1 2022.
827 funds tracked by Wall St. Rank held GSK as of Q2 2023.

Based on Autumn Glory Partners's 13F filing for Q2 2023, filed 2 Aug 2023.